| OMB APPROVAL | |
| OMB Number:3235-0101 | |
| Expires:December 31, 2009 | |
| Estimated
average burden
hours
per response 2.00
|
| SEC USE ONLY | |
| DOCUMENT SEQUENCE NO. | |
| CUSIP NUMBER | |
| WORK LOCATION |
|
ATTENTION:
|
Transmit for filing 3 copies
of this form concurrently with either placing an order with a broker to
execute sale
|
|
|
or
executing a sale directly with a market maker.
|
|
1 (a)
NAME OF ISSUER (Please type or
print)
INVO
Bioscience, Inc.
|
(b)
IRS IDENT. NO.
20-4036208
|
(c)
S.E.C. FILE NO.
333-147330
|
|||||
|
1 (d)
ADDRESS OF
ISSUER STREET CITY
STATE
ZIP CODE
|
(e)
TELEPHONE NO.
|
||||||
|
100
Cummings
Center,
Suite
421E Beverly
MA
01915
|
AREA
CODE
978
|
NUMBER
878-9505
|
|||||
|
2
(a)
NAME OF PERSON FOR WHOSE ACCOUNT THE SECURITIES ARE TO BE
SOLD
Claude
Ranoux
|
(b)
RELATIONSHIP TO ISSUER
President
& Director
|
(c) ADDRESS STREET CITY STATE ZIP
CODE
8
Chestnut
Street, Winchester MA 01890
|
|||||
|
3 (a)
|
(b)
|
SEC
USE ONLY
|
(c)
|
(d)
|
(e)
|
(f)
|
(g)
|
||
|
Title
of the
Class
of
Securities
To
Be Sold
|
Name
and Address of Each Broker Through Whom the Securities
are to be Offered or Each Market Maker who
is Acquiring the Securities
|
Broker-Dealer
File
Number
|
Number
of Shares
or
Other Units
To
Be Sold
(See
instr. 3(c))
|
Aggregate
Market
Value
(See
instr. 3(d))
|
Number
of Shares
or
Other Units
Outstanding
(See
instr. 3(e))
|
Approximate
Date
of Sale
(See
instr. 3(f))
(MO. DAY YR.)
|
Name
of Each
Securities
Exchange
(See
instr. 3(g))
|
||
|
Common
Stock
|
Mr.
Arlen J.
FOX,
Morgan
Stanley, 125 High Street, Boston, MA
|
75,000
in blocks of 5,000 shares
|
$30,000
|
58,002,763
|
Start
12 / 30 / 09
|
OTCBB
|
|||
|
INSTRUCTIONS:
|
3.
(a)Title of the class of securities to be sold
|
||||||||
|
1.
(a)Name of issuer
|
(b)Name and address of each
broker through whom the securities are intended to be
sold
|
||||||||
|
(b)Issuer’s I.R.S. Identification
Number
|
(c)Number of shares or other
units to be sold (if debt securities, give the aggregate face
amount)
|
||||||||
|
(c)Issuer’s S.E.C. file number, if
any
|
(d)Aggregate market value of
the securities to be sold as of a specified date within 10 days prior to
the filing of this notice
|
||||||||
|
(d)Issuer’s address, including zip
code
|
(e)Number of shares or other
units of the class outstanding, or if debt securities the face amount
thereof outstanding, as
|
||||||||
|
(e)Issuer’s telephone number,
including area code
|
shown by the most recent report
or statement published by the issuer
|
||||||||
|
(f)Approximate date on which
the securities are to be sold
|
|||||||||
|
2.
(a)Name of person for whose account the securities are to be
sold
|
(g)Name of each securities
exchange, if any, on which the securities are intended to be
sold
|
||||||||
|
(b)Such person’s relationship to
the issuer (e.g., officer, director, 10%stockholder, or member of immediate
family of any of the foregoing)
|
|||||||||
|
(c)Such person’s address,
including zip code
|
|||||||||
|
Title
of the
Class
|
Date
you Acquired
|
Nature
of Acquisition Transaction
|
Name
of Person from Whom Acquired
(If
gift, also give date donor acquired)
|
Amount
of Securities Acquired
|
Date
of Payment
|
Nature
of Payment
|
|
Common
|
12/5/08
|
Founder
shares converted in Share Exchange
|
Directly
from the company, INVO Bioscience, Inc.
|
25,501,473
|
12/23/2006
|
Assets
(patents, molds and inventory) contributed to Company
|
| INSTRUCTIONS: | If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid. | |||||
|
Name
and Address of Seller
|
Title
of Securities Sold
|
Date
of Sale
|
Amount
of
Securities
Sold
|
Gross
Proceeds
|
|
None
|
|
INSTRUCTIONS:
See the definition of “person” in paragraph (a) of Rule 144.
Information is to be given not only as to the person for whose account the
securities are to be sold but also as to all other persons included in
that definition. In addition, information shall be given as to sales by
all persons whose sales are required by paragraph (e) of Rule 144 to be
aggregated with sales for the account of the person filing this
notice.
|
ATTENTION:
The person for whose account the securities to which this notice
relates are to be sold hereby represents by signing this notice that he
does not know any material adverse information in regard to the current
and prospective operations of the Issuer of the securities to be sold
which has not been publicly disclosed. If each person has
adopted a written trading plan or given trading instructions to satisfy
Rule 10b5-1 under the Exchange Act, by signing the form and indicating the
date that the plan was adopted or the instruction given, that person makes
such representation as of the plan adoption or instruction
date.
|
|
|
12/30/2009
DATE OF
NOTICE
|
/s/
Claude Ranoux
(SIGNATURE)
|
|
__________________________________________________
DATE
OF PLAN ADOPTION OR GIVING OF INSTRUCTION,
IF RELYING ON RULE
10B5-1
|
The notice shall be signed
by the person for whose account the securities are to be
sold. At least one copy
of the notice shall be manually signed. Any copies not manually
signed shall bear typed o printed
signatures.
|
||
|
ATTENTION: Intentional
misstatements or omission of facts constitute Federal Criminal Violations
(See 18 U.S.C. 1001)
|